Daniel Lochner

Daniel Lochner, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Oyster Point Pharma, Inc. and Tectonic Therapeutic, Inc. The record holds 21 filings, for trades running from 4 November 2019 to 25 September 2026.

Purchases make up the whole of the open-market record (3 purchases, €440k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 9 share grants and 7 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €109k. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 2 October 2026: a share grant of €11k, in Tectonic Therapeutic, Inc. The most recent open-market purchase was published on 11 February 2026, 255 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.